nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.10.2008 | Research Paper

Epithelial mesenchymal transition traits in human breast cancer cell lines

verfasst von: T. Blick, E. Widodo, H. Hugo, M. Waltham, M. E. Lenburg, R. M. Neve, E. W. Thompson

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Epithelial mesenchymal transition (EMT) has long been associated with breast cancer cell invasiveness and evidence of EMT processes in clinical samples is growing rapidly. Genome-wide transcriptional profiling of increasingly larger numbers of human breast cancer (HBC) cell lines have confirmed the existence of a subgroup of cell lines (termed Basal B/Mesenchymal) with enhanced invasive properties and a predominantly mesenchymal gene expression signature, distinct from subgroups with predominantly luminal (termed Luminal) or mixed basal/luminal (termed Basal A) features (Neve et al Cancer Cell 2006). Studies providing molecular and cellular analyses of EMT features in these cell lines are summarised, and the expression levels of EMT-associated factors in these cell lines are analysed. Recent clinical studies supporting the presence of EMT-like changes in vivo are summarised. Human breast cancer cell lines with mesenchymal properties continue to hold out the promise of directing us towards key mechanisms at play in the metastatic dissemination of breast cancer.

Duband JL, Monier F, Delannet M, Newgreen D (1995) Epithelium-mesenchyme transition during neural crest development. Acta Anat (Basel) 154(1):63–78CrossRef

Prindull G, Zipori D (2004) Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 103(8):2892–2899PubMedCrossRef

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142PubMedCrossRef

Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24(37):5764–5774PubMedCrossRef

Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17(5):548–558PubMedCrossRef

Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198(1):11–26PubMed

Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15(6):740–746PubMedCrossRef

Frisch SM, Screaton RA (2001) Anoikis mechanisms. Curr Opin Cell Biol 13(5):555–562PubMedCrossRef

Barrallo-Gimeno A, Nieto MA (2005) The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132(14):3151–3161PubMedCrossRef

10.

Przybylo JA, Radisky DC (2007) Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail’s pace. Int J Biochem Cell Biol 39(6):1082–1088PubMedCrossRef

11.

Thomson S, Buck E, Petti F et al (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65(20):9455–9462PubMedCrossRef

12.

Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65(14):5996–6000 discussion -1PubMedCrossRef

13.

Thompson EW, Newgreen DF, Tarin D (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65(14):5991–5995 discussion 5PubMedCrossRef

14.

Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66(17):8319–8326PubMedCrossRef

15.

Aigner K, Dampier B, Descovich L et al (2007) The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26(49):6979–6988PubMedCrossRef

16.

Hlubek F, Spaderna S, Schmalhofer O, Jung A, Kirchner T, Brabletz T (2007) Wnt/FZD signaling and colorectal cancer morphogenesis. Front Biosci 12:458–470PubMedCrossRef

17.

Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172(7):973–981PubMedCrossRef

18.

Liu Y (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15(1):1–12PubMedCrossRef

19.

Zeisberg M, Kalluri R (2004) The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 82(3):175–181PubMedCrossRef

20.

Zeisberg M, Yang C, Martino M, Duncan M, Rieder F, Tanjore H, Kalluri R (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282(32):23337–23347

21.

Mercado-Pimentel ME, Runyan RB (2007) Multiple transforming growth factor-beta isoforms and receptors function during epithelial-mesenchymal cell transformation in the embryonic heart. Cells Tissues Organs 185(1–3):146–156PubMedCrossRef

22.

Arciniegas E, Frid MG, Douglas IS, Stenmark KR (2007) Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 293(1):L1–L8PubMedCrossRef

23.

Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428PubMedCrossRef

24.

Thompson EW, Paik S, Brunner N et al (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150(3):534–544PubMedCrossRef

25.

Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP (1992) Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 52(19):5190–5197PubMed

26.

Gilles C, Polette M, Zahm J, Tournier J, Volders L, Foidart J, Birembaut P (1999) Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 112(Pt 24):4615–4625PubMed

27.

Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP (1994) Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31(2–3):325–335PubMedCrossRef

28.

Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147(3):631–644PubMedCrossRef

29.

Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 148(4):779–790PubMedCrossRef

30.

Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 185(1–3):191–203PubMedCrossRef

31.

Hendrix MJ, Seftor EA, Seftor RE, Trevor KT (1997) Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150(2):483–495PubMed

32.

Jungert K, Buck A, von Wichert G, Adler G, Konig A, Buchholz M, Gress TM, Ellenrieder V (2007) Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 67(4):1563–1570PubMedCrossRef

33.

Vasko V, Espinosa AV, Scouten W et al (2007) Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 104(8):2803–2808PubMedCrossRef

34.

Gilles C, Newgreen D, Sato H, Thompson EW (2004) Matrix Metalloproteases and epithelial-to mesenchymal transition: implications for carcinoma metastasis In: P Savagner (ed) Rise and fall of epithelial phenotype (webversion at www.eurekah.com). Landes Bioscience Publishers, Georgetown, TX, pp 297–315

35.

Giunciuglio D, Culty M, Fassina G et al (1995) Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 63(6):815–822PubMedCrossRef

36.

Kim HJ, Litzenburger BC, Cui X et al (2007) Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 27(8):3165–3175PubMedCrossRef

37.

Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H (2007) NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26(5):711–724PubMedCrossRef

38.

Li GC, Wang ZY (2006) Constitutive expression of RbAp46 induces epithelial-mesenchymal transition in mammary epithelial cells. Anticancer Res 26(5A):3555–3560PubMed

39.

Perou CM, Jeffrey SS, van de Rijn M et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96(16):9212–9217PubMedCrossRef

40.

Thompson EW, Torri J, Sabol M et al (1994) Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis 12(3):181–194PubMedCrossRef

41.

Galliher AJ, Schiemann WP (2006) Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8(4):R42PubMedCrossRef

42.

Planas -Silva MD, Waltz PK (2007) Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 104(1–2):11–21PubMedCrossRef

43.

Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB (2006) Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 66(23):11370–11380PubMedCrossRef

44.

Whitehead RH, Bertoncello I, Webber LM, Pedersen JS (1983) A new human breast carcinoma cell line (PMC42) with stem cell characteristics. I. Morphologic characterization. J Natl Cancer Inst 70(4):649–661PubMed

45.

Whitehead RH, Monaghan P, Webber LM, Bertoncello I, Vitali AA (1983) A new human breast carcinoma cell line (PMC42) with stem cell characteristics. II. Characterization of cells growing as organoids. J Natl Cancer Inst 71(6):1193–1203PubMed

46.

Whitehead RH, Quirk SJ, Vitali AA, Funder JW, Sutherland RL, Murphy LC (1984) A new human breast carcinoma cell line (PMC42) with stem cell characteristics. III. Hormone receptor status and responsiveness. J Natl Cancer Inst 73(3):643–648PubMed

47.

Hugo, Ackland ML, Lawrence MG, Clements JA, Williams ED, Thompson EW (2007) Epithelial––mesenchymal and mesenchymal––epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383

48.

Ackland ML, Michalczyk A, Whitehead RH (2001) PMC42, A novel model for the differentiated human breast. Exp Cell Res 263(1):14–22PubMedCrossRef

49.

Lebret SC, Newgreen DF, Waltham MC, Price JT, Thompson EW, Ackland ML (2006) Myoepithelial molecular markers in human breast carcinoma PMC42-LA cells are induced by extracellular matrix and stromal cells. In vitro Cell Dev Biol Anim 42(10):298–307PubMed

50.

Ackland ML, Newgreen D, Price JT, Fridman M, Waltham M, Arvanitis A, Minichiello J, Thompson EW (2003) Epidermal growth factor stimulates epithelio-mesenchymal transition in the stable human breast carcinoma cell line variant PMC42-LA. Lab Invest 83(3):435–448PubMed

51.

Lebret SC, Newgreen DF, Thompson EW, Ackland ML (2007) Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors. Breast Cancer Res 9(1):R19PubMedCrossRef

52.

Thiery JP (2002) Epithelial to mesenchymal transitions in tumour progression. Nature Cancer 2:442–454CrossRef

53.

Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66(23):11271–11278PubMedCrossRef

54.

Chaffer CL, Dopheide B, McCulloch DR, Lee AB, Moseley JM, Thompson EW, Williams ED (2005) Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin Exp Metastasis 22(2):115–125PubMedCrossRef

55.

Come C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P (2006) Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 12(18):5395–5402PubMedCrossRef

56.

Ross DT, Scherf U, Eisen MB et al (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227–235PubMedCrossRef

57.

Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 Melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104(1):13–19PubMedCrossRef

58.

Zajchowski DA, Bartholdi MF, Gong Y et al (2001) Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61(13):5168–5178PubMed

59.

Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83(3):249–289PubMedCrossRef

60.

Lombaerts M, van Wezel T, Philippo K et al (2006) E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 94(5):661–671PubMed

61.

Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25(15):2273–2284PubMedCrossRef

62.

Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–577PubMedCrossRef

63.

El Ghouzzi V, Legeai-Mallet L, Aresta S, Benoist C, Munnich A, de Gunzburg J, Bonaventure J (2000) Saethre-Chotzen mutations cause TWIST protein degradation or impaired nuclear location. Hum Mol Genet 9(5):813–819PubMedCrossRef

64.

Chen B, Lim RW (1997) Physical and functional interactions between the transcriptional inhibitors Id3 and ITF-2b. Evidence toward a novel mechanism regulating muscle-specific gene expression. J Biol Chem 272(4):2459–2463PubMedCrossRef

65.

Maira SM, Wurtz JM, Wasylyk B (1996) Net (ERP/SAP2) one of the Ras-inducible TCFs, has a novel inhibitory domain with resemblance to the helix-loop-helix motif. Embo J 15(21):5849–5865PubMed

66.

Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194(10):701–704PubMed

67.

Gilles C, Thompson EW (1996) The epithelial to mesenchymal transition and metastatic progression in carcinoma. The Brea J 2:83–96CrossRef

68.

Korsching E, Packeisen J, Liedtke C et al (2005) The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206(4):451–457PubMedCrossRef

69.

Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA (2002) Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 21(20):3241–3246PubMedCrossRef

70.

Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen CY (2001) Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20(29):3814–3823PubMedCrossRef

71.

Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005) Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103(8):1631–1643PubMedCrossRef

72.

Moody SE, Perez D, Pan TC et al (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8(3):197–209PubMedCrossRef

73.

Martin TA, Goyal A, Watkins G, Jiang WG (2005) Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 12(6):488–496PubMedCrossRef

74.

Come C, Arnoux V, Bibeau F, Savagner P (2004) Roles of the transcription factors snail and slug during mammary morphogenesis and breast carcinoma progression. J Mammary Gland Biol Neoplasia 9(2):183–193PubMedCrossRef

75.

Mironchik Y, Winnard PT Jr., Vesuna F et al (2005) Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 65(23):10801–10809PubMedCrossRef

76.

Aigner K, Descovich L, Mikula M et al (2007) The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett 581(8):1617–1624PubMedCrossRef

77.

Turashvili G, Bouchal J, Baumforth K et al (2007) Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7:55PubMedCrossRef

78.

Dupont VN, Gentien D, Oberkampf M, De Rycke Y, Blin N (2007) A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 121(5):1036–1046PubMedCrossRef

79.

Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS, Argani P, Sukumar S (2006) HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 66(19):9527–9534PubMedCrossRef

80.

Castro Alves C, Rosivatz E, Schott C, Hollweck R, Becker I, Sarbia M, Carneiro F, Becker KF (2007) Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol 211(5):507–515PubMedCrossRef

81.

Alonso SR, Tracey L, Ortiz P et al (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67(7):3450–3460PubMedCrossRef

82.

Chung CH, Parker JS, Ely K et al (2006) Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-{kappa}B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66(16):8210–8218PubMedCrossRef

83.

Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW (2007) Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50(5):648–658PubMedCrossRef

84.

Uchikado Y, Natsugoe S, Okumura H, Setoyama T, Matsumoto M, Ishigami S, Aikou T (2005) Slug Expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 11(3):1174–1180PubMed

85.

Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446(7136):690–694PubMedCrossRef

86.

Horikawa T, Yang J, Kondo S, Yoshizaki T, Joab I, Furukawa M, Pagano JS (2007) Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res 67(5):1970–1978PubMedCrossRef

87.

Lee TK, Poon RT, Yuen AP et al (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12(18):5369–5376PubMedCrossRef

88.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3):319–326

89.

Buck E, Eyzaguirre A, Barr S et al (2007) Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6(2):532–541PubMedCrossRef

90.

Yang AD, Fan F, Camp ER et al (2006) Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12(14 Pt 1):4147–4153PubMedCrossRef

91.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef

92.

Ross DT, Perou CM (2001) A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers 17(2):99–109PubMed

93.

Kenny PA, Lee GY, Myers CA et al (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84–96PubMedCrossRef

94.

Hugo, Ackland ML, Lawrence MG, Clements JA, Williams ED, Thompson EW (2007) Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383

95.

Thompson EW, Waltham M, Ramus SJ, Hutchins AM, Armes JE, Campbell IG, Williams ED, Thompson PR, Rae JM, Johnson MD, Clarke R (2004) LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. Clin Exp Metastasis 21(6):535–541PubMedCrossRef

96.

Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F (2001) The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7(6):1267–1278PubMedCrossRef

97.

Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, Noel A, van Roy F, Berx G, Foidart JM, Gilles C (2006) Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 25(36):4975–4985PubMedCrossRef

98.

Espineda CE, Chang JH, Twiss J, Rajasekaran SA, Rajasekaran AK (2004) Repression of Na, K-ATPase beta1-subunit by the transcription factor snail in carcinoma. Mol Biol Cell 15(3):1364-1373PubMedCrossRef

99.

Okubo T, Truong TK, Yu B, Itoh T, Zhao J, Grube B, Zhou D, Chen S (2001) Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH). Cancer Res 61(4):1338–1346PubMed

100.

Rennstam K, Jonsson G, Tanner M, Bendahl PO, Staaf J, Kapanen AI, Karhu R, Baldetorp B, Borg A, Isola J (2007) Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet 172(2):95–106PubMedCrossRef

Titel: Epithelial mesenchymal transition traits in human breast cancer cell lines
verfasst von: T. Blick
E. Widodo
H. Hugo
M. Waltham
M. E. Lenburg
R. M. Neve
E. W. Thompson
Publikationsdatum: 01.10.2008
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 6/2008
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9170-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Epithelial mesenchymal transition traits in human breast cancer cell lines

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model

Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development

Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression

E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie